Lilly's Weekly Insulin Onswik Clears FDA
- The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, offering an alternative to daily long-acting injections.
- Approval drew on the QWINT trial program in over 3,400 patients, where Onswik's blood-sugar control was comparable to daily insulin glargine or degludec.
- Onswik is the second once-weekly basal insulin cleared in the US, after Novo Nordisk's Awiqli (icodec); Lilly expects US availability within months.
💡 Points
Second mover, not first: Onswik only claims non-inferiority to daily glargine/degludec in QWINT, so Lilly can't out-argue Awiqli on efficacy — it has to out-sell it, bundling weekly insulin into the same reps and formulary contracts as Trulicity/Mounjaro. Insulin, the industry's most commoditized category, just became the GLP-1 giants' next cross-sell battleground.